TAICHUNG, Jan. 12,
2025 /PRNewswire/ -- The Taiwan National Innovation
Awards, regarded as the pinnacle of excellence in the biomedical
and healthcare sectors, recognize the most transformative
breakthroughs that push boundaries and redefine global standards.
At the 21st annual awards in 2024, the China Medical University
(CMU) and Healthcare System achieved an extraordinary milestone,
sweeping 17 awards across three prestigious categories: two
Corporate Innovation Awards, six Academic-Research Innovation
Awards, and nine Clinical Innovation Awards. This unparalleled
success cements CMU and Healthcare System's position
as a trailblazer in biotechnology, smart healthcare, and innovative
medical devices.
A shining example of CMU and Healthcare System's
innovative prowess is the groundbreaking CAR001 cell therapy
developed by its spin-off, Ever Supreme Bio Technology. This
revolutionary treatment employs allogeneic CAR and BiTE-GDT
technologies to target solid tumors with unprecedented precision.
Utilizing artificial intelligence, the research team identified
HLA-G as a critical target for solid tumors, enabling the
development of the CAR001 (CAR-T) technique. In preclinical animal
trials, this breakthrough therapy achieved an astounding 90% tumor
eradication rate, with results published in world-leading medical
journals. The therapy has also received Phase I and IIa clinical
trial approvals in both Taiwan and
the United States, marking a
pivotal step toward clinical application.
Adding to the excitement, CMU and Healthcare
System's innovations were showcased during the highly
anticipated "Demo Day" segment of the awards.
This platform features the most exceptional teams presenting their
work to top Taiwanese investors for live evaluation and feedback.
Ever Supreme Bio Technology stood out as one of the ten chosen
teams, further underscoring the global potential and competitive
edge of its technology.
CMU and Healthcare System's achievements extend
beyond cutting-edge therapies. Its pioneering use of artificial
intelligence spans critical areas, including drug discovery,
myocardial infarction treatment, infection and sepsis management,
remote dialysis, image analysis, and medical education. Moreover,
CMU and Healthcare System has redefined possibilities in
exosome-based technology, offering transformative solutions for
cancer and neurodegenerative diseases such as
Parkinson's. The precision of its targeted exosome
delivery system significantly enhances treatment outcomes,
heralding new hope for patients with conditions once considered
intractable.
As a hub of innovation, CMU and Healthcare System exemplifies
the synergy between research excellence and global collaboration.
By forging partnerships with world-class academic and medical
institutions, CMU and Healthcare System is accelerating the
clinical adoption of groundbreaking technologies. Its unwavering
commitment to advancing biomedical and smart healthcare innovation
is transforming patient care and driving profound, lasting impact
on the global stage.
The future of healthcare has never looked brighter—and CMU and
Healthcare System is at the forefront, leading the charge.
Media contact:
Carolyn Chen,
100709@tool.caaumed.org.tw
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cmu-and-healthcare-system-secures-unprecedented-17-awards-at-the-2024-taiwan-national-innovation-awards-302348629.html
SOURCE China Medical University Hospital
